COMP <GO>
AVXL vs ARMP // EV/EBITDA & P/E VALUATION
Anavex Life Sciences Corp. (NASDAQ) VS. Armata Pharmaceuticals Inc. (NYSE) • 15-METRIC TALLY: AVXL 0
— ARMP 3
■ METRIC PARITY
LAST: $1.19 (-8.46%) • MKT CAP: $120.5M
valuation
—
LAST: $3.28 (+0.92%) • MKT CAP: $120.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVXL VS. ARMP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVXL | ARMP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -21.77% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | ARMP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.2 | 43.8 | -12.64 | ARMP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $120.5M | $120.8M | -$335.5K | ARMP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVXL REV | ARMP REV | AVXL GROSS % | ARMP GROSS % | AVXL FCF | ARMP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$39.0M | -$26.3M |
| FY 2024 | $0 | $0 | — | — | -$30.8M | -$39.4M |
| FY 2023 | $0 | $0 | — | — | -$27.8M | -$47.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVXL // BETA —
ARMP // BETA —